Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04936035 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
A Phase 2 study of Hypertension, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 394
- Enrollment target
- 20
- Study locations
NCT04936035 is a Phase 2 study of Hypertension that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 394 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04936035, a Phase 2 study of Hypertension, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 394 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-AGT01
Study Locations (20)
Florida
- Clinical Trial Site - Clearwater
- Clinical Trial Site - Coral Gables
- Clinical Trial Site - Fleming Island
- Clinical Trial Site - Hollywood
- Clinical Trial Site - Hollywood
- Clinical Trial Site - Inverness
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Miami
California
- Clinical Trial Site - Beverly Hills
- Clinical Trial Site - La Mesa
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - San Diego
- Clinical Trial Site - South Gate
- Clinical Trial Site - Vista
Arizona
- Clinical Trial Site - Tempe
- Clinical Trial Site - Tempe
Alabama
- Clinical Trial Site - Birmingham
District of Columbia
- Clinical Trial Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04936035
The ClinicalTrials.gov registry entry for NCT04936035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04936035 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04936035 about?
NCT04936035 is a clinical study titled "A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension". The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
What is the current status of trial NCT04936035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 394 participants. The study started on 2021-07-07. Estimated completion is 2024-12-05.
What conditions does trial NCT04936035 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT04936035?
The interventions under investigation include: Placebo (DRUG), ALN-AGT01 (DRUG).
Who is sponsoring clinical trial NCT04936035?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04936035 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.